Ipravent Respules 2 Ml

What Are Ipravent Respules 2 Ml?

• Infants, young children, and elderly patients who cannot coordinate conventional inhaler technique
• Patients in acute respiratory distress who lack the physical ability to perform an active inhalation manoeuvre
• Patients on home nebulisation programmes requiring regular Ipratropium Bromide therapy
• Ventilated or hospitalised patients in intensive care or respiratory ward settings

What Are Ipravent Respules 2 Ml Used For?

COPD – Maintenance Bronchodilation & Exacerbation Management

Asthma – Acute Exacerbation Adjunct Therapy

Bronchospasm in Surgical & ICU Patients

How Do Ipravent Respules Work?

Anticholinergic Mechanism – Blocking Vagal Bronchoconstriction

• Bronchodilation via M3 blockade: Parasympathetic (vagal) nerve stimulation releases acetylcholine, which binds M3 muscarinic receptors on bronchial smooth muscle — triggering contraction and narrowing of the airways. Ipratropium competitively blocks these M3 receptors, preventing acetylcholine binding and allowing bronchial smooth muscles to relax and widen.
• Reduction of mucus hypersecretion: Muscarinic M3 receptors on submucosal mucous glands also mediate excessive mucus secretion in COPD and asthma. Ipratropium's M3 blockade reduces this pathological mucus overproduction, improving mucociliary clearance and reducing airway obstruction from mucus plugging.
• cGMP degradation: Ipratropium promotes degradation of cyclic guanosine monophosphate (cGMP) within airway smooth muscle cells — lowering intracellular calcium availability and directly reducing smooth muscle contractile tone, contributing to bronchodilation through a secondary mechanism.
• Minimal systemic absorption — key safety advantage: As a quaternary ammonium compound, Ipratropium Bromide is poorly lipid-soluble and carries a permanent positive charge — properties that prevent it from crossing the blood-brain barrier or the bronchial epithelium into systemic circulation in significant amounts. This means the bronchodilator effect is localised to the airways, with negligible cardiovascular or CNS side effects at therapeutic nebulised doses.

How to Use Ipravent Respules 2 Ml with a Nebuliser

• Wash hands thoroughly before handling any nebuliser components or respule vials.
• Assemble the nebuliser: Set up your jet or ultrasonic nebuliser according to the manufacturer's instructions. Ensure the nebuliser cup, tubing, mouthpiece or face mask are clean and dry.
• Open the respule: Separate one respule from the strip. Hold upright, twist off the top firmly — do not cut with scissors.
• Transfer the solution: Squeeze all the contents of the opened respule directly into the nebuliser cup. If combining with salbutamol or sodium chloride as directed by your physician, add these to the cup first, then add Ipratropium — gently swirl to mix.
• Use immediately after opening: Ipravent Respules are preservative-free — use the entire vial contents at once and do not store opened vials for later use. Discard any unused solution.
• Fit the mouthpiece or mask: A mouthpiece is preferred over a face mask for adults to maximise pulmonary deposition. If a mask is used, ensure a snug seal and avoid mist entering the eyes — Ipratropium mist in the eyes can cause acute angle-closure glaucoma.
• Begin nebulisation: Connect the tubing to the air compressor pump and switch on. Breathe slowly and deeply through the mouthpiece until no more visible mist is produced (approximately 10–15 minutes).
• At the end: A sputtering sound from the nebuliser cup signals the treatment is complete. Switch off the compressor, disassemble, and clean the nebuliser cup and accessories as per manufacturer instructions after every use.
• Eye protection: If using a face mask, cover the eyes or shield them to prevent any aerosol mist contact — particularly important in patients with pre-existing glaucoma or narrow-angle anatomy.

Ipravent Respules 2 Ml Dosage Guidelines

Key Benefits of Ipravent Respules 2 Ml

• COPD-Specific Bronchodilator of Choice: As a SAMA anticholinergic agent, Ipratropium Bromide directly targets the dominant driver of COPD bronchoconstriction — cholinergic vagal tone — making it pharmacologically more rational for COPD maintenance than short-acting beta-agonists alone.
• Dual-Mechanism Power When Combined with Salbutamol: Combining Ipratropium Bromide (anticholinergic) with salbutamol (beta-2 agonist) in the same nebuliser cup produces complementary, synergistic bronchodilation through two independent pathways — providing superior airway opening than either agent alone in both acute and chronic settings.
• Nebuliser Delivery – Ideal for Vulnerable Patients: Nebuliser therapy eliminates the need for inhalation coordination — making Ipravent Respules accessible and effective for the youngest patients, the elderly, the critically ill, and anyone who cannot reliably use a conventional pMDI or DPI.
• Minimal Systemic Side Effects: The quaternary ammonium structure of Ipratropium Bromide prevents systemic absorption — delivering potent airway bronchodilation without the cardiovascular stimulant effects (tachycardia, tremor, hypertension) associated with beta-2 agonist bronchodilators.
• Preservative-Free Single-Dose Respules: The unit-dose format eliminates preservative-related bronchial irritation (e.g. benzalkonium chloride sensitivity) and removes any risk of cross-contamination or microbiological degradation associated with multi-dose nebuliser solutions.
• Evidence-Based Inclusion in International Guidelines: Ipratropium Bromide nebulisation is recommended in GOLD COPD guidelines, GINA asthma guidelines, and WHO essential medicines lists — underpinned by over four decades of clinical evidence.
• Effective 4–6 Hour Duration: Unlike short-acting beta-2 agonists (3–4 hour duration), Ipratropium's 4–6 hour bronchodilatory window means 3–4 daily nebulisations provide near-continuous coverage throughout waking hours without the need for extremely frequent dosing.
• Cipla Manufacturing Quality: Manufactured by Cipla Ltd. — a global pharmaceutical leader with WHO GMP-certified production facilities — Ipravent Respules guarantee consistent quality, sterility, and precise Ipratropium Bromide dosing in every vial.

Common Side Effects of Ipravent Respules 2 Ml

Commonly Reported (Mild & Usually Transient)

• Dry mouth (xerostomia): The most frequently reported side effect — caused by anticholinergic suppression of salivary gland secretion. Drinking water after nebulisation helps. Usually mild and decreases with continued use.
• Bitter or metallic taste in the mouth: Common immediately after nebulisation; harmless and transient
• Headache: Mild, occasional; usually self-resolving
• Throat irritation or dryness: Particularly common if mouthpiece seal is imperfect or residual mist is inhaled through the nose
• Cough: Occasional; caused by aerosol deposition on upper airways rather than a pharmacological effect
• Nausea: Mild, infrequent; generally resolves quickly
• Constipation: Anticholinergic effect on gastrointestinal motility; more notable with long-term high-dose use

Less Common – Require Medical Attention

• Paradoxical bronchospasm: Rare worsening of breathlessness immediately after nebulisation — discontinue immediately and use a rescue SABA. Switch to an alternative formulation and contact your prescriber
• Acute angle-closure glaucoma: Occurs if nebulised mist enters the eyes — presenting as sudden severe eye pain, blurred vision, coloured halos, nausea, and vomiting. This is an ocular emergency. Prevent by using a well-fitted mouthpiece; if a mask is used, ensure it is snug and eyes are protected
• Urinary retention: More likely in men with benign prostatic hyperplasia (BPH) or pre-existing bladder neck obstruction. Report difficulty urinating to your prescriber immediately
• Tachycardia or palpitations: Occasional at higher doses; more significant with systemic anticholinergic exposure. Monitor heart rate in patients with pre-existing arrhythmias
• Skin flushing: Mild; anticholinergic vasodilatory effect

Who Should Not Use Ipravent Respules?

• Known hypersensitivity to Ipratropium Bromide, atropine, or any atropine derivative
• Allergy to soy lecithin or related food products: NOTE — the nebuliser solution does NOT contain soy lecithin (only the former CFC MDI inhaler did). Ipravent Respules are safe for patients with soy or peanut allergy
• Use as the sole therapy for acute severe asthma: Always combine with salbutamol in acute severe asthma — Ipratropium is an adjunct, not a standalone rescue agent

Key Drug Interactions

Ipravent Respules vs Other Bronchodilator Options

Storage Instructions for Ipravent Respules 2 Ml

• Store at room temperature between 15°C and 30°C (59°F–86°F) in a cool, dry location
• Keep respules in their original sealed foil pouch until ready to use — the foil protects from light degradation
• Do not refrigerate or freeze — cold storage is not required and may affect solution clarity
• Protect from direct sunlight and heat sources
• Keep out of reach of children and pets
• Once a respule is opened, use the entire contents immediately — do not store opened vials for later use
• Do not use if the solution appears discoloured, cloudy, or contains particles
• Check the expiry date on each strip and outer carton before use — never use expired respules

Why Order Ipravent Respules 2 Ml from Ed Care Store?

• Authentic Cipla Ltd. Products: All Ipravent Respules are sourced from verified supply chains — Cipla-manufactured, WHO GMP-certified, preservative-free, and fully genuine.
• Discreet, Secure Packaging: Every order is dispatched in tamper-evident, plain packaging — protecting your health privacy at every step of delivery.
• Competitive Generic Pricing: Access to Cipla's globally trusted Ipratropium Bromide nebuliser solution at affordable prices — making daily COPD nebuliser therapy financially sustainable for patients who rely on it long-term.
• Complete Respiratory Range: Browse the complete respiratory medicines collection — including ICS + LABA combination inhalers, corticosteroid-only inhalers, systemic steroids, and rescue bronchodilators — all available in one trusted place.
• Men's Health Products Available: Men managing concurrent health needs alongside respiratory care can also access Digihaler SF 250 Inhaler and other products on the same platform.
• Health Information Resources: Visit the Ed Care Store health blog for informational reading on respiratory health management, nebuliser care, and treatment strategies.